Shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) have garnered a consensus rating of “Moderate Buy” from seven analysts currently covering the stock, as reported by MarketBeat Ratings. Among these analysts, one has assigned a hold rating, while six have issued buy recommendations, reflecting a generally positive outlook on the company’s performance.
Analysts have recently updated their price targets for Ligand Pharmaceuticals, with the average one-year target set at approximately $239.33. Notable upgrades include a report from Oppenheimer, which raised its price objective from $190.00 to $250.00 and provided an “outperform” rating on November 3, 2023. Meanwhile, the Royal Bank of Canada adjusted its target from $234.00 to $235.00, also assigning an “outperform” rating in a report dated December 10, 2023.
Furthermore, Citigroup initiated coverage with a buy rating and set a price objective of $270.00 on December 9, 2023. HC Wainwright raised its price target from $206.00 to $231.00 on November 6, 2023, while Weiss Ratings maintained a “hold (c)” rating in a note published on December 29, 2023.
Institutional Investments and Market Performance
Recent activity from institutional investors highlights a growing interest in Ligand Pharmaceuticals. The Royal Bank of Canada increased its stake by 25.8% during the first quarter, now holding 6,120 shares valued at approximately $644,000 after acquiring an additional 1,256 shares. Additionally, AQR Capital Management LLC entered a new position worth $344,000.
Other significant movements include MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., which raised its stake by 8.2%, bringing its total to 10,660 shares valued at around $1.12 million. UBS AM, a distinct business unit of UBS Asset Management Americas LLC, also increased its holdings by 9.8%, now owning 55,327 shares worth $5.82 million. Lastly, Jane Street Group LLC significantly boosted its position by 176.2%, holding 36,922 shares valued at approximately $3.88 million. Currently, institutional investors and hedge funds own 91.28% of Ligand Pharmaceuticals’ stock.
Despite these positive indicators, Ligand Pharmaceuticals saw its stock price decrease by 1.9% recently. On the last trading day, shares opened at $186.32. The stock has experienced a 50-day moving average of $193.98 and a 200-day moving average of $183.38. Over the past year, the stock has fluctuated between a low of $93.58 and a high of $212.49. Ligand Pharmaceuticals has a market capitalization of $3.67 billion, a price-to-earnings ratio of 90.01, and a beta of 1.14.
Company Overview
Ligand Pharmaceuticals is a biopharmaceutical company specializing in acquiring, developing, and out-licensing proprietary technologies to assist pharmaceutical and biotechnology firms in discovering and developing new medicines. With a focus on building a diversified portfolio of technology platforms, the company partners with industry leaders to advance therapeutic candidates across various disease areas. Ligand’s operations primarily revolve around its research services and royalty-generating businesses.
As analysts continue to express confidence in Ligand Pharmaceuticals, the company’s strategic partnerships and technological advancements may further solidify its position in the market.
